June 13, 2018
InSysBio LLC (www.insysbio.com), a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world’s leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).
The aim of collaboration is to develop a comprehensive QSP platform of COPD and its treatment including detailed description of immune cell dynamics, effect of cigarette smoke, extracellular matrix remodeling and other aspects of disease progression.
About InSysBio
InSysBio (formerly Institute for System Biology Moscow) was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of quantitative systems pharmacology (QSP) modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published a lot of scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | October 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
1.
02 Oct 2025 13:23
InSysBio to announce participation in BioTechX Europe 2025 with focus on AI and QSP
InSysBio announces their participation in BioTechX Europe 2025. Oleg Demin, Chief Scientific Advisor and co-founder of InSysBio, and Igor Goryanin, Professor at University of Edinburgh, will host a roundtable discussion entitled, "Integrating Artificial Intelligence with Quantitative Systems Pharmacology (QSP): Opportunities and Challenges"
|
3
|
4
|
5
| ||
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
1.
16 Oct 2025 12:13
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
InSysBio launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data to be added to InSysBio’s CYTOCON or fIVE databases for use in QSP modeling, analysis, or decision-making. The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
|
29
1.
29 Oct 2025 15:08
The project aims at mechanistic PK/RO modeling to predict optimal dose and regimen of BGB-B2033, GPC3 x 4-1BB bispecific antibody
InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with BeOne Medicines, a global oncology company.
|
30
|
31
| ||
Thank you for your message! We will get back to you shortly.
